Adage Capital Partners Gp, L.L.C. Curis Inc Transaction History

Adage Capital Partners Gp, L.L.C.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.71 - $2.43 $142,000 - $486,000	-200,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$4.45 - $8.09 $16.5 Million - $29.9 Million	-3,700,000 Reduced 94.87%	200,000 $952,000
Q3 2021 Nov 15, 2021	SELL	$6.94 - $8.85 $8.33 Million - $10.6 Million	-1,200,000 Reduced 23.53%	3,900,000 $30.5 Million
Q2 2021 Aug 16, 2021	SELL	$7.45 - $16.27 $10.4 Million - $22.8 Million	-1,400,000 Reduced 21.54%	5,100,000 $41.2 Million
Q1 2021 May 17, 2021	BUY	$8.78 - $12.8 $30.7 Million - $44.7 Million	3,495,400 Added 116.33%	6,500,000 $73.6 Million
Q4 2020 Feb 16, 2021	BUY	$1.08 - $8.2 $3.24 Million - $24.6 Million	3,004,600 New	3,004,600 $24.6 Million

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.